NCT05076760View on ClinicalTrials.gov

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2031

Conditions
Solid TumorAdvanced CancerMetastatic CancerNon Small Cell Lung CancerCutaneous Squamous Cell CarcinomaMerkel Cell CarcinomaMelanomaPancreatic CancerTriple Negative Breast CancerHead and Neck Cancer
Interventions
BIOLOGICAL

MEM-288 Intratumoral Injection

Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).

BIOLOGICAL

Nivolumab

anti-PD1 monoclonal antibody

DRUG

Docetaxel

75 mg/m2 intravenous administration every 3 weeks

Trial Locations (2)

27710

COMPLETED

Duke Cancer Institute, Durham

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

collaborator

Duke Cancer Institute

OTHER

lead

Memgen, Inc.

INDUSTRY

NCT05076760 - MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter